TrialAlzheimer's research & therapy2019

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Michael F Egan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.